Epstein Files Search

triumph for Regeneron Pharmaceuticals, the Tarrytown,IM -based biotechnology company that invented it. Pralucnt is likely to be more widely used, and to cost more, than Wall Stott analysts expected ... medicine from Amgen is also expected to be approved soon. The FDA is clearing Pralucnt for patients with heterozygous familial hypercholesterolemit a genetic condition that causes high cholesterol ... high as $4.8 billion. In the survey, doctors expressed a preference for Pralucnt. One advantage of Regencron's drug is that doctors will be able to start